IQWiG finds no additional benefit in Eklira Genuair (Almiral) in COPD treatment
IQWiG reports in a preliminary review of data of Eklira Genuair/Bretaris Genuair (aclidinium bromide) from Almiral compared to Spiriva (tiotropium) offers no additional benefit to COPD patients.
IQWiG is the German review organisation that carries out assessments under AMNOG for the G-BA which has the final decision in Germany.Some studies were too short and others had shortcomings. According to IQWiG studies must last at least 6 months in order to be reliable.
Almiral considered this review contrasts with the decision of EMA to recommend the drug for treatment of COPD for study periods from 12 to 24 weeks. Almiral has until 23 January to comment on the review.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins